These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16098367)

  • 1. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
    Taplin ME; George DJ; Halabi S; Sanford B; Febbo PG; Hennessy KT; Mihos CG; Vogelzang NJ; Small EJ; Kantoff PW
    Urology; 2005 Aug; 66(2):386-91. PubMed ID: 16098367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
    Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
    Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
    Leibovitch I; Pinthus Y; Sella BA; Ramon J
    Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.
    George DJ; Halabi S; Shepard TF; Sanford B; Vogelzang NJ; Small EJ; Kantoff PW
    Clin Cancer Res; 2005 Mar; 11(5):1815-20. PubMed ID: 15756004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.
    George DJ; Halabi S; Shepard TF; Vogelzang NJ; Hayes DF; Small EJ; Kantoff PW;
    Clin Cancer Res; 2001 Jul; 7(7):1932-6. PubMed ID: 11448906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating chromogranin a and hormone refractory prostate cancer chemotherapy.
    Cabrespine A; Guy L; Gachon F; Curé H; Chollet P; Bay JO
    J Urol; 2006 Apr; 175(4):1347-52. PubMed ID: 16515996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
    Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
    Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice.
    Dowling AJ; Czaykowski PM; Krahn MD; Moore MJ; Tannock IF
    J Urol; 2000 May; 163(5):1481-5. PubMed ID: 10751862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
    Sciarra A; Di Silverio F
    Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
    Berruti A; Bollito E; Cracco CM; Volante M; Ciccone G; Porpiglia F; Papotti M; Scarpa RM; Dogliotti L
    Prostate; 2010 May; 70(7):718-26. PubMed ID: 20087896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine differentiation in stage D2 prostate cancers.
    Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
    Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
    Bok RA; Halabi S; Fei DT; Rodriquez CR; Hayes DF; Vogelzang NJ; Kantoff P; Shuman MA; Small EJ
    Cancer Res; 2001 Mar; 61(6):2533-6. PubMed ID: 11289126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The chromogranin-A (CgA) in prostate cancer.
    Ranno S; Motta M; Rampello E; Risino C; Bennati E; Malaguarnera M
    Arch Gerontol Geriatr; 2006; 43(1):117-26. PubMed ID: 16280180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
    Sasaki T; Komiya A; Suzuki H; Shimbo M; Ueda T; Akakura K; Ichikawa T
    Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
    Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
    Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of circulating chromogranin A in prostate cancer.
    Hirano D; Minei S; Sugimoto S; Yamaguchi K; Yoshikawa T; Hachiya T; Kawata N; Yoshida T; Takahashi S
    Scand J Urol Nephrol; 2007; 41(4):297-301. PubMed ID: 17763220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
    Marszalek M; Wachter J; Ponholzer A; Leitha T; Rauchenwald M; Madersbacher S
    Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease.
    Berruti A; Mosca A; Porpiglia F; Bollito E; Tucci M; Vana F; Cracco C; Torta M; Russo L; Cappia S; Saini A; Angeli A; Papotti M; Scarpa RM; Dogliotti L
    J Urol; 2007 Sep; 178(3 Pt 1):838-43; quiz 1129. PubMed ID: 17631319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma.
    Cussenot O; Villette JM; Valeri A; Cariou G; Desgrandchamps F; Cortesse A; Meria P; Teillac P; Fiet J; Le Duc A
    J Urol; 1996 Apr; 155(4):1340-3. PubMed ID: 8632569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria.
    Banu E; Banu A; Medioni J; Levy E; Thiounn N; Mejean A; Andrieu JM; Oudard S
    Prostate; 2007 Oct; 67(14):1543-9. PubMed ID: 17705243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.